Anti-arrhythmic action of nadolol, a beta-adrenergic receptor blocking agent.
The anti-arrhythmic action of 2,3-cis-1,2,3,4-tetrahydro-5-[(2-hydroxy-3-tert-butylamino)propoxy]2,3-naphthalenediol (nadolol) was evaluated and compared with that of propranolol in several experimental models of cardiac arrhythmias. Both nadolol and propranolol antagonized isoproterenol-induced tachycardia and ouabain-induced arrhythmias in cats, antagonized coronary artery ligation-induced ventricular fibrillation and suppressed ventricular ectopic activity during vagal stimulation in dogs. In contrast to propranolol, nadolol was considerably weaker in suppressing existing digoxin-induced arrhythmias, lacked local anesthetic activity and did not depress the heart in dogs. Because of these findings, it is concluded that the anti-arrhythmic activity of nadolol is apparently related to blockade of beta-adrenergic receptors.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D004285:Dogs; D004558:Electric Stimulation; D006321:Heart / Q000503:physiopathology; D006329:Heart Conduction System / Q000187:drug effects; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D008297:Male; D009284:Naphthols / Q000494:pharmacology; D009431:Neural Conduction / Q000187:drug effects; D010042:Ouabain / Q000037:antagonists & inhibitors; D011412:Propanolamines / Q000494:pharmacology*; D014630:Vagus Nerve / Q000502:physiology; D014693:Ventricular Fibrillation / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D009284:Naphthols; D011412:Propanolamines; D010042:Ouabain; D007545:Isoproterenol